189 related articles for article (PubMed ID: 23902710)
1. Targeting mixed lineage kinases in ER-positive breast cancer cells leads to G2/M cell cycle arrest and apoptosis.
Wang L; Gallo KA; Conrad SE
Oncotarget; 2013 Aug; 4(8):1158-71. PubMed ID: 23902710
[TBL] [Abstract][Full Text] [Related]
2. The investigational Aurora kinase A inhibitor alisertib (MLN8237) induces cell cycle G2/M arrest, apoptosis, and autophagy via p38 MAPK and Akt/mTOR signaling pathways in human breast cancer cells.
Li JP; Yang YX; Liu QL; Pan ST; He ZX; Zhang X; Yang T; Chen XW; Wang D; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():1627-52. PubMed ID: 25834401
[TBL] [Abstract][Full Text] [Related]
3. Anti-tumor activity of SL4 against breast cancer cells: induction of G
Wang LH; Jiang XR; Chen GL; Guo W; Zhang JY; Cui LJ; Li HH; Li M; Liu X; Yang JY; Wu CF
Sci Rep; 2016 Nov; 6():36486. PubMed ID: 27819344
[TBL] [Abstract][Full Text] [Related]
4. Benzopyran derivative CDRI-85/287 induces G2-M arrest in estrogen receptor-positive breast cancer cells via modulation of estrogen receptors α- and β-mediated signaling, in parallel to EGFR signaling and suppresses the growth of tumor xenograft.
Saxena R; Fatima I; Chandra V; Blesson CS; Kharkwal G; Hussain MK; Hajela K; Roy BG; Dwivedi A
Steroids; 2013 Nov; 78(11):1071-86. PubMed ID: 23891847
[TBL] [Abstract][Full Text] [Related]
5. Differential insulin-like growth factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells.
Bartucci M; Morelli C; Mauro L; Andò S; Surmacz E
Cancer Res; 2001 Sep; 61(18):6747-54. PubMed ID: 11559546
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of mixed-lineage kinase (MLK) activity during G2-phase disrupts microtubule formation and mitotic progression in HeLa cells.
Cha H; Dangi S; Machamer CE; Shapiro P
Cell Signal; 2006 Jan; 18(1):93-104. PubMed ID: 15923109
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of the p38 kinase suppresses the proliferation of human ER-negative breast cancer cells.
Chen L; Mayer JA; Krisko TI; Speers CW; Wang T; Hilsenbeck SG; Brown PH
Cancer Res; 2009 Dec; 69(23):8853-61. PubMed ID: 19920204
[TBL] [Abstract][Full Text] [Related]
8. Juglanin induces apoptosis and autophagy in human breast cancer progression via ROS/JNK promotion.
Sun ZL; Dong JL; Wu J
Biomed Pharmacother; 2017 Jan; 85():303-312. PubMed ID: 27899257
[TBL] [Abstract][Full Text] [Related]
9. A kinase inhibitor screen identifies Mcl-1 and Aurora kinase A as novel treatment targets in antiestrogen-resistant breast cancer cells.
Thrane S; Pedersen AM; Thomsen MB; Kirkegaard T; Rasmussen BB; Duun-Henriksen AK; Lænkholm AV; Bak M; Lykkesfeldt AE; Yde CW
Oncogene; 2015 Aug; 34(32):4199-210. PubMed ID: 25362855
[TBL] [Abstract][Full Text] [Related]
10. Autocrine IGF-I/insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation.
Fox EM; Kuba MG; Miller TW; Davies BR; Arteaga CL
Breast Cancer Res; 2013; 15(4):R55. PubMed ID: 23844554
[TBL] [Abstract][Full Text] [Related]
11. Cep-1347 (KT7515), a semisynthetic inhibitor of the mixed lineage kinase family.
Maroney AC; Finn JP; Connors TJ; Durkin JT; Angeles T; Gessner G; Xu Z; Meyer SL; Savage MJ; Greene LA; Scott RW; Vaught JL
J Biol Chem; 2001 Jul; 276(27):25302-8. PubMed ID: 11325962
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of the c-Jun N-terminal kinase signaling pathway by the mixed lineage kinase inhibitor CEP-1347 (KT7515) preserves metabolism and growth of trophic factor-deprived neurons.
Harris CA; Deshmukh M; Tsui-Pierchala B; Maroney AC; Johnson EM
J Neurosci; 2002 Jan; 22(1):103-13. PubMed ID: 11756493
[TBL] [Abstract][Full Text] [Related]
13. Estrogen suppresses MLK3-mediated apoptosis sensitivity in ER+ breast cancer cells.
Rangasamy V; Mishra R; Mehrotra S; Sondarva G; Ray RS; Rao A; Chatterjee M; Rana B; Rana A
Cancer Res; 2010 Feb; 70(4):1731-40. PubMed ID: 20145118
[TBL] [Abstract][Full Text] [Related]
14. CDK9 inhibitors selectively target estrogen receptor-positive breast cancer cells through combined inhibition of MYB and MCL-1 expression.
Mitra P; Yang RM; Sutton J; Ramsay RG; Gonda TJ
Oncotarget; 2016 Feb; 7(8):9069-83. PubMed ID: 26812885
[TBL] [Abstract][Full Text] [Related]
15. Delta MEKK3:ER* activation induces a p38 alpha/beta 2-dependent cell cycle arrest at the G2 checkpoint.
Garner AP; Weston CR; Todd DE; Balmanno K; Cook SJ
Oncogene; 2002 Nov; 21(53):8089-104. PubMed ID: 12444545
[TBL] [Abstract][Full Text] [Related]
16. RL71, a second-generation curcumin analog, induces apoptosis and downregulates Akt in ER-negative breast cancer cells.
Yadav B; Taurin S; Larsen L; Rosengren RJ
Int J Oncol; 2012 Sep; 41(3):1119-27. PubMed ID: 22710975
[TBL] [Abstract][Full Text] [Related]
17. Prolonged extracellular signal-regulated kinase 1/2 activation during fibroblast growth factor 1- or heregulin beta1-induced antiestrogen-resistant growth of breast cancer cells is resistant to mitogen-activated protein/extracellular regulated kinase kinase inhibitors.
Thottassery JV; Sun Y; Westbrook L; Rentz SS; Manuvakhova M; Qu Z; Samuel S; Upshaw R; Cunningham A; Kern FG
Cancer Res; 2004 Jul; 64(13):4637-47. PubMed ID: 15231676
[TBL] [Abstract][Full Text] [Related]
18. Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors.
Patel HK; Tao N; Lee KM; Huerta M; Arlt H; Mullarkey T; Troy S; Arteaga CL; Bihani T
Breast Cancer Res; 2019 Dec; 21(1):146. PubMed ID: 31852484
[TBL] [Abstract][Full Text] [Related]
19. KX-01, a novel Src kinase inhibitor directed toward the peptide substrate site, synergizes with tamoxifen in estrogen receptor α positive breast cancer.
Anbalagan M; Carrier L; Glodowski S; Hangauer D; Shan B; Rowan BG
Breast Cancer Res Treat; 2012 Apr; 132(2):391-409. PubMed ID: 21509526
[TBL] [Abstract][Full Text] [Related]
20. Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53.
Bacus SS; Gudkov AV; Lowe M; Lyass L; Yung Y; Komarov AP; Keyomarsi K; Yarden Y; Seger R
Oncogene; 2001 Jan; 20(2):147-55. PubMed ID: 11313944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
